Congress trades
Artivion, Inc. (AORT)
About Artivion, Inc.
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- James Patrick Mackin
- Employees
- 1,800
- Listed since
- Feb 12, 1993
- Market value
- $1.2B
- Price to earnings
- -
- Earnings per share
- -$0.07
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 6, 2026 | -$0.28 | $0.00 | $125.8M | $120.0M | EPS missRevenue beat |
| Q1 FY2026reported May 7, 2026 | $0.03 | $0.06 | $116.3M | $115.7M | EPS missRevenue in line |
| Q4 FY2025reported Feb 12, 2026 | $0.05 | $0.14 | $116.0M | $116.5M | EPS missRevenue in line |
| Q3 FY2025reported Nov 6, 2025 | $0.16 | $0.14 | $113.4M | $110.4M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | $0.03 | $0.11 | $113.0M | $108.0M | EPS missRevenue beat |
| Q1 FY2025reported May 5, 2025 | -$0.01 | $0.12 | $99.0M | $94.8M | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 1, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| J. Patrick MackinChairman, President and Chief Executive Officer | $835K | $5.0M | $1.0M | $6.9M |
| Lance A. BerryExecutive Vice President, Chief Operating Officer, Chi | $526K | $2.0M | $491K | $3.0M |
| John E. DavisSenior Vice President, Chief Commercial Officer | $441K | $1.2M | $282K | $2.0M |
| Jean F. HollowaySenior Vice President, General Counsel, Corporate Secr | $438K | $1.2M | $281K | $1.9M |
| Marshall S. StantonSenior Vice President, Clinical Research and Chief Med | $444K | $935K | $281K | $1.7M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in AORT
7 disclosures of 7 on record · median 28d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr.Filed late | Stock | Purchase | $1,001 - $15,000 | -2.0%S&P +1.6% · vs S&P 500 -3.5% | Jul 16, 2026 | Sep 4, 2026 | 50d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -37.5%S&P +13.6% · vs S&P 500 -51.1% | Oct 9, 2025 | Nov 18, 2025 | 40d |
| Tina SmithSpouse | Stock | Purchase | $50,001 - $100,000 | +79.0%S&P +69.4% · vs S&P 500 +9.6% | Nov 16, 2023 | Nov 20, 2023 | 4d |
| Tina SmithSpouse | Stock | Purchase | $50,001 - $100,000 | +89.2%S&P +73.1% · vs S&P 500 +16.1% | Nov 10, 2023 | Nov 20, 2023 | 10d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +61.2%S&P +69.8% · vs S&P 500 -8.6% | Jul 14, 2023 | Aug 21, 2023 | 38d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +56.6%S&P +74.7% · vs S&P 500 -18.1% | Jun 13, 2023 | Jul 11, 2023 | 28d |
| Tina SmithSpouse | Stock | Purchase | $50,001 - $100,000 | +89.5%S&P +106.4% · vs S&P 500 -16.9% | Sep 23, 2022 | Oct 17, 2022 | 24d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
3 members · estimate, as of Sep 10, 20263 members report a position (estimated). The largest estimated position is in the $250,001 - $500,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Tina Smith | Democrat · Senate | $250,001 - $500,000 | 22.6% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Josh Gottheimer | Democrat · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded AORT?
Gilbert Ray Cisneros, Jr., Tina Smith, Josh Gottheimer disclosed AORT transactions in the filings shown here.
Which members of Congress hold AORT?
3 members of Congress report a position in AORT in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to Tina Smith, Gilbert Ray Cisneros, Jr. and Josh Gottheimer. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are AORT trades disclosed?
Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.